Navigation Links
Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B
Date:12/6/2010

ORLANDO, Fla., Dec. 6, 2010 /PRNewswire-USNewswire/ -- Investigators report no evidence of toxicity in the four hemophilia B patients enrolled to date in a gene therapy trial using a vector under development at St. Jude Children's Research Hospital and UCL (University College London) to correct the inherited bleeding disorder.

This trial was designed primarily as a safety test, with low and intermediate doses of the vector expected to produce little detectable Factor IX. The Factor IX protein helps the blood form clots. Individual with hemophilia B lack adequate levels of this clotting factor. The first participant in the open-label Phase I/II trial had an unexpectedly high level of Factor IX expression after receiving the lowest dose of the vector being tested in this study. Levels of the Factor IX protein rose from less than 1 percent to 2 percent of normal after the experimental vector was infused into the patient.

The patient's Factor IX production remains elevated more than nine months later. Since the infusion the patient has also not suffered any spontaneous joint bleeds or needed prophylactic treatment.

Study data was presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) by Amit Nathwani, M.D., Ph.D., UCL Department of Hematology, and National Health Service Blood and Transplant, UK, the study's first author. Andrew Davidoff, M.D., chair of the St. Jude Department of Surgery, is the senior author.

Work on the vector began more than 10 years ago in the St. Jude laboratory of Arthur Nienhuis, M.D., member of the Department of Hematology and a study co-author. The collaboration continued after Nathwani returned to London.

The trial vector was made by packaging a codon-optimized version of the Factor IX gene into a member of the adeno-associated virus (AAV) family known as AAV8. AAV8 was picked because the incidence of natural infection with AAV8 is low and, like other AAVs, targe
'/>"/>

SOURCE St. Jude Children's Research Hospital
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. LSU’s Jayne Garno receives early career award from President
2. NOVAVAX Awarded Nearly $1 Million in Grants from IRS Under Qualifying Therapeutic Discovery Project
3. Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
4. Osteotech Announces Early Termination of HSR Waiting Period
5. EarlySenses EverOn(R) Central Display Station (CDS) Receives FDA Clearance
6. Neuro-Biotechs Solution for a Doctor near You: Early Detection for Alzheimers and Chronic Fatigue Syndrome!
7. Deloitte Recap Honors Sanofi-aventis and Exelixis With the Allicense 2010 Breakthrough Alliance Award for Early-Stage Collaboration in Cancer
8. West Michigan Launches $10 Million Early Stage Venture Fund to Support Life Science & Technology
9. New Study Demonstrates Clinical Validity of EarlyCDT-Lung™
10. Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer
11. New test takes guesswork out of diagnosing early stage Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a ... Drug Administration (FDA) for the use of Medtronic,s ... (including a newly developed catheter) for use with ... intravenously to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ... and forecasts of the revenue and share analysis. ...
(Date:12/24/2014)... Bethesda, MD (PRWEB) December 23, 2014 ... signed into law H.R. 83, the Omnibus and ... the first time, made hydrocephalus a condition eligible ... Research Programs (CDMRP) administered by the Department of ... conjunction with its allies on Capitol Hill, is ...
(Date:12/24/2014)... 2014 The report expects global cell ... 2019. It also provides a carefully analyzed data about ... for the market. , Full Copy of Report @ ... global market for cell expansion will keep witnessing growth ... this growth to be driven by rapid technological advancements, ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... Experience to the Leader in ... Cellular Bioenergetic Profiling, N. BILLERICA, ... for real-time measurement of cellular,bioenergetics in microplates, announced today that ... company,s Board of,Directors. In this position, Keegan will apply his ...
... Cadus Corporation (OTC,Bulletin Board: KDUS) announced today financial results for ... for the second quarter of 2007 and for the same ... was $218,960, compared,to net income of $75,387 for the same ... quarter of 2007 was $0.02, compared to basic net,income per ...
... a Phase II study of R1507 ... for the Treatment of Sarcoma, ... its partner, Roche has initiated a Phase II,clinical study of R1507 ... created by Genmab under the company,s,agreement with Roche and initiation of ...
Cached Biology Technology:Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors 2Cadus Reports Second Quarter 2007 Results 2Cadus Reports Second Quarter 2007 Results 3Cadus Reports Second Quarter 2007 Results 4Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma 2
(Date:12/22/2014)... DENVER , Dec. 22, 2014  The ... for the biometrics industry as Acuity Market Intelligence ... biometrics may finally be open. Acuity forecasts that ... mobile devices that incorporate biometrics will drive a ... 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has ... North America Perimeter Security Systems Market" report to ... The North American perimeter security market is ... 2014 to 2019. Although the U.S. market holds a ... is expected to grow at a higher CAGR ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ... its team and bring LaunchKey to market in 2015. ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... announced today that they have entered into ... its proprietary photocleavable biotin reagent for the ... The biggest constraint on successful ... is achieving sufficient sensitivity. SomaLogic,s innovative SOMAmer ...
... 29, 2011) The future brightened for organic chemistry when ... attach organic molecules to pristine graphene, making the miracle material ... lab of chemist James Tour, building upon a set of ... method that turned what was a single-atom-thick sheet of carbon ...
... A team of scientists from Worcester Polytechnic Institute ... Life Sciences and Bioengineering Center, have regenerated functional muscle ... clinical therapy to treat people who suffer major muscle ... coax mature human muscle cells into a stem cell-like ...
Cached Biology News:Graphene lights up with new possibilities 2Graphene lights up with new possibilities 3Body rebuilding: Researchers regenerate muscle in mice 2Body rebuilding: Researchers regenerate muscle in mice 3
...
Hygromycin resistance gene (hph), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... template is designed to allow neomycin/kanamycin selection ... FRT-PGK-gb2-neo-FRT template encodes the neomycin/kanamycin resistance gene ... expression of kanamycin resistance in E.coli ... expression of neomycin resistance in mammalian cells. ...
... This depletion cocktail is tailored ... cells from suspensions of rat ... using the StemSep (or compatible ... selection system. The CD4+ T ...
Biology Products: